Also trades as: RAD.AX (ASX) · $vol 0M
RADX NASDAQ
Radiopharm Theranostics Limited
1W: -12.1%
1M: -32.9%
3M: -66.7%
YTD: -71.9%
1Y: -74.7%
$1.42
-0.06 (-4.05%)
Weekly Expected Move ±15.7%
$1
$1
$1
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$4M
+1114.3% ▲
3Y CAGR: +643.8%
Gross Profit
$39K
-86.9% ▼
3Y CAGR: +64.5%
Operating Income
-$38M
-4.2% ▼
Net Income
-$38M
+20.0% ▲
EPS (Diluted)
$-5.28
+85.3% ▲
EBITDA
-$38M
+13.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Revenue | $9K | $292K | $299K | $4M |
| YoY Growth | +0.0% | +3210.6% | +2.3% | +1114.3% |
| Cost of Revenue | $0 | $0 | $0 | $4M |
| Gross Profit | $9K | $292K | $299K | $39K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 1.1% |
| R&D Expenses | $4M | $14M | $18M | $28M |
| SG&A Expenses | $11M | $13M | $15M | $17M |
| Operating Expenses | $20M | $35M | $37M | $38M |
| Operating Income | -$20M | -$35M | -$37M | -$38M |
| Operating Margin | -225527.7% | -11803.3% | -12238.4% | -1050.6% |
| Interest Expense | $9M | $86K | $643K | $65K |
| Income Before Tax | -$30M | -$35M | -$48M | -$38M |
| Tax Expense | $44K | $38K | $96K | $103K |
| Net Income | -$30M | -$35M | -$48M | -$38M |
| Net Margin | -343550.9% | -11838.6% | -16024.3% | -1055.3% |
| EPS (Diluted) | $-29.76 | $-33.00 | $-36.00 | $-5.28 |
| EBITDA | -$18M | -$31M | -$44M | -$38M |
| Shares Outstanding | 1M | 1M | 1M | 7M |